We are live on ! Find out more
CH

CVI Holdings Portfolio holdings

AUM $116M
1-Year Est. Return 5.68%
This Fund
S&P 500
This Quarter Est. Return
+6.43%
1 Year Est. Return
+5.68%
3 Year Est. Return
+25.77%
5 Year Est. Return
+327.29%
10 Year Est. Return
AUM
$266M
AUM Growth
-$519M
Cap. Flow
-$520M
Cap. Flow %
-195.59%
Top 10 Hldgs %
24.71%
Holding
657
New
41
Increased
1
Reduced
224
Closed
243
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FSRX
526
DELISTED
FinServ Acquisition Corp. II Class A Common Stock
FSRX
-72,735
Closed -$730K
ROSE
527
DELISTED
Rose Hill Acquisition Corporation Class A Ordinary Shares
ROSE
-162,195
Closed -$1.7M
LHC
528
DELISTED
Leo Holdings Corp. II
LHC
-97,500
Closed -$984K
JGGC
529
DELISTED
Jaguar Global Growth Corporation I Class A Ordinary Shares
JGGC
-74,900
Closed -$766K
PRPC
530
DELISTED
CC Neuberger Principal Holdings III
PRPC
-74,698
Closed -$754K
NVOS
531
DELISTED
Novo Integrated Sciences, Inc. Common Stock
NVOS
-149,453
Closed -$301K
AAC
532
DELISTED
Ares Acquisition Corporation
AAC
-950,718
Closed -$9.57M
TRCA
533
DELISTED
Twin Ridge Capital Acquisition Corp.
TRCA
-400,000
Closed -$4.04M
CXAC.WS
534
DELISTED
C5 Acquisition Corporation Public warrants, each whole public warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
CXAC.WS
-49,100
Closed -$1.47K
CXAC
535
DELISTED
C5 Acquisition Corporation
CXAC
-100,000
Closed -$1.02M
FSNB
536
DELISTED
Fusion Acquisition Corp. II
FSNB
-522,438
Closed -$5.25M
SSU.WS
537
DELISTED
SIGNA Sports United N.V. Public Warrants, each whole warrant to purchase one Ordinary Shares at an exercise price of $11.50
SSU.WS
-18,758
Closed -$1.49K
SAMA
538
DELISTED
Schultze Special Purpose Acquisition Corp. II Class A Common Stock
SAMA
-24,478
Closed -$247K
SAMAW
539
DELISTED
Schultze Special Purpose Acquisition Corp. II Warrant
SAMAW
-11,939
Closed -$133
FZT
540
DELISTED
FAST Acquisition Corp. II
FZT
-159,764
Closed -$1.6M
ADERW
541
DELISTED
26 Capital Acquisition Corp Warrant
ADERW
-13,972
Closed -$3.49K
PIAI
542
DELISTED
Prime Impact Acquisition I
PIAI
-322,266
Closed -$3.31M
ATAQ
543
DELISTED
Altimar Acquisition Corp III
ATAQ
-494,400
Closed -$4.98M
CCAI
544
DELISTED
Cascadia Acquisition Corp. Class A Common Stock
CCAI
-50,000
Closed -$506K
AGAC
545
DELISTED
African Gold Acquisition Corp
AGAC
-415,598
Closed -$4.18M
AMRS
546
DELISTED
Amyris Inc.
AMRS
-18,164,553
Closed -$27.8M
AFTR
547
DELISTED
AfterNext HealthTech Acquisition Corp
AFTR
-11,043
Closed -$111K
GENQ
548
DELISTED
Genesis Unicorn Capital Corp. Class A Common Stock
GENQ
-60,000
Closed -$610K
BBIG
549
PUT
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
-1,585
Closed -$14.6K
BLNGW
550
DELISTED
Belong Acquisition Corp. Warrant
BLNGW
-17,150
Closed -$2.4K

Similar funds

CVI Holdings's Q1 2023 Portfolio in Review

As of Q1 2023, CVI Holdings held 657 positions worth $266M, down 66% from $784M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

CVI Holdings withdrew a net $520M in Q1 2023, closing 243 positions and reducing 224 holdings. Its most notable exit was ImmunityBio, an estimated $38.6M position sold in full.

By sector, the portfolio is most concentrated in Financials at 68% of assets, up from 64% a quarter earlier, followed by Healthcare and Technology.

Against the trend, CVI Holdings opened a new position in GeneDx Holdings worth $3.56M.

  • CVI Holdings's largest Q1 2023 buy was GeneDx Holdings: 295,706 shares worth $3.56M.
  • CVI Holdings added most to TPG Pace Beneficial II Corp. in Q1 2023, an estimated $82.2K increase.
  • CVI Holdings's biggest Q1 2023 reduction was RTB Digital, cutting an estimated $1.96M.
  • CVI Holdings fully exited ImmunityBio in Q1 2023, selling an estimated $38.6M.
  • CVI Holdings's ten largest holdings make up 25% of its $266M portfolio in Q1 2023.
  • CVI Holdings opened 41 new positions and closed 243 in Q1 2023.
  • CVI Holdings's portfolio value fell 66% quarter-over-quarter to $266M.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.